[Real life visual and anatomic outcomes of aflibercept treatment for treatment-naive patients with exudative age-related macular degeneration].
Anti-VEGF therapies have revolutionized the treatment of neovascular age-related macular degeneration (AMD).


OBJECTIVE
The goal of this study was to evaluate the "real life" visual and anatomical outcomes of aflibercept treatment for treatment-naive patients with exudative AMD.


METHODS
This was a retrospective study of patients treated with aflibercept in the department of Ophthalmology at the University Hospital of Bordeaux between November 2013 and July 2015. The follow-up period varied from 3months to 2years. All patients received an induction phase with 3monthly intravitreal injections (IVT) followed by personalized monitoring. ETDRS best-corrected visual acuity (BCVA), fundus examination and OCT were performed at each visit. Data were collected at day 0, 3 months, 6, 9, 12months, 18 and 24months.


RESULTS
Forty-three eyes of forty patients, mean age 77.7years, were included, with a minimum of 3months follow-up. Twenty-five eyes were followed for 1year; 5 eyes for two years. At baseline, the mean BCVA was 55.7 letters. Patients received 7.5 injections on average the first year and 2.6 the 2nd year. The mean gain of visual acuity was +7.3 letters at 3 months, +6.2 letters at 12 months, and +6.8 letters at 2years. Anatomically, the OCT data showed a decline of all parameters. The central macular thickness decreased by 118.3μm at 3months, 136.4μm at 12months and 65.5μm at 2years.


CONCLUSIONS
Aflibercept can achieve effective visual and anatomical outcomes with results, which approach the pivotal studies, despite the use of personalized protocols and longer monitoring intervals.
Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Rabat-Leon, 33000 Bordeaux, France. Electronic address: marievictoireduval@hotmail.fr.
M-V
MV
Duval
Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Rabat-Leon, 33000 Bordeaux, France.
M-B
MB
Rougier
Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Rabat-Leon, 33000 Bordeaux, France; University Bordeaux, ISPED, 33000 Bordeaux, France; Inserm, U1219, Bordeaux Population Health Research Center, 33000 Bordeaux, France.
M-N
MN
Delyfer
Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Rabat-Leon, 33000 Bordeaux, France.
F
F
Combillet
Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Rabat-Leon, 33000 Bordeaux, France; University Bordeaux, ISPED, 33000 Bordeaux, France; Inserm, U1219, Bordeaux Population Health Research Center, 33000 Bordeaux, France.
J-F
JF
Korobelnik
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects; D063171:Corneal Pachymetry; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage / Q000009:adverse effects; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects* / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab
Acuité visuelle; Aflibercept; Anti-VEGF; Central macular thickness; Dégénérescence maculaire liée à l’âge exsudative; Exudative age-related macular degeneration; Patient naïf; Ranibizumab; Treatment-naive patient; Visual acuity; Épaisseur maculaire centrale